Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
A father of a child with Down's Syndrome is challenging a local authority's (LA) decision to cease funding his 22 year old daughter's education. He wants her education to continue until she is 25.
This case will hopefully clarify LA obligations around when they can lawfully cease to maintain a statement of SEN. Current guidance recommends LAs maintain statements until the age of 19. Yet the proportion of children and young adults with Down’s Syndrome staying longer in schools continues to increase. If the Court of Appeal decides that a LA should educate a pupil with SEN until they reach 25, it will force LAs to carefully examine the provision for these individuals alongside younger students, both practically (e.g. safeguarding) and financially.
The outcome of this case is awaited by many interested parties. However, the Court of Appeal have rightly reserved judgement to a later date. This case will require careful scrutiny and a sound grasp of the wide-ranging consequences on all those affected by the decision.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Associate
Select which mailings you would like to receive from us.
Sign up